HOME >> BIOLOGY >> NEWS
Scientists develop new concept with potential to help predict how individuals may respond to drugs

Scientists from Imperial College London and Pfizer have developed a new method that could predict individual patient responses to drug treatments. The authors anticipate that the development will advance biomedical research further towards development of personalised medicines.

Research published today in Nature demonstrates the new 'pharmaco-metabonomic' approach that uses a combination of advanced chemical analysis and mathematical modelling to predict drug-induced responses in individual patients. The method is based on analysis of the body's normal metabolic products, metabolites, and metabolite patterns that are characteristic of the individual. The authors hypothesize that these individual patterns can be used to diagnose diseases, predict an individual's future illnesses, and their responses to treatments.

Not all drugs are effective in all patients and in rare cases adverse drug reactions can occur in susceptible individuals. To address this, researchers from Imperial College and Pfizer have been exploring new methods for profiling individuals prior to drug therapy. The new approach, if successful, requires the analysis of the metabolite profiles of an individual from a urine, or other biofluid, sample.

The researchers tested their approach by administering paracetamol to rats and measuring how it affected their livers and how it was excreted. Before giving the dose they measured the levels of the natural metabolites in the rats' urine. Metabolites being small molecules produced by normal body functions, they can indicate a body's drug response. After creating a 'pre-dose urinary profile' for each rat, the researchers used computer modelling to relate the nature of the pre-dose metabolite profile to the nature of the post-dose response.

Professor Jeremy Nicholson, from Imperial College London, who led the research, says: "This new technique is potentially of huge importance to the future of healthcare and the pharmaceuti
'"/>

Contact: Tony Stephenson
at.stephenson@imperial.ac.uk
44-207-594-6712
Imperial College London
19-Apr-2006


Page: 1 2

Related biology news :

1. Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes
2. Scientists prove that disputed Korean stem cell line comes from an unfertilized egg and not cloning
3. Scientists move closer to bio-engineered bladders
4. Scientists find stem cell switch
5. Scientists discover new way to study nanostructures
6. Scientists a step closer to understanding how anaesthetics work in the brain
7. Scientists to make news at Computational Biology Conference
8. Accident-prone? Scientists link brain function to knee injuries
9. Scientists take next step in understanding potential target for ovarian cancer treatment
10. Scientists find brown fat master switch
11. Scientists identify 2 distinct Parkinsons networks

Post Your Comments:
(Date:7/23/2014)... The drought that has the entire country in its grip ... may also be responsible for the proliferation of a heat-loving ... rivers and hot springs, which the drought has made warmer ... died of an infection caused by this parasite after swimming ... the nose of an individual and travels to the brain. ...
(Date:7/23/2014)... available in German . ... cells, drive metabolic processes and transmit signals. To perform ... Scientists at the Max Planck Institute for Developmental Biology ... constructed of similar amino acid chains even when their ... that exist today arose from common precursors. Presumably, in ...
(Date:7/23/2014)... 2014 BioCatch, the global leader ... it has been named in Gartner,s Market Guide for ... Gartner,s well-known Magic Quadrant for Web Fraud Detection. ... of several vendors to deliver passive biometric analysis and ... standard feature of at least 30% of one-stop fraud ...
Breaking Biology News(10 mins):Diseases of another kind 2Protein evolution follows a modular principle 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
(Date:7/23/2014)... July 23, 2014 ... of Trendlines Agtech , announced it has ... Israel,s leading agricultural thermoplastics applications companies. ... Valentis,s technology combines nanocrystalline cellulose (NCC), a biodegradable, ... additional nanoparticles to produce highly improved polymeric films. ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... Calif. , July 23, 2014  Sofinnova Ventures, ... firm, today announced the closing of Sofinnova Venture Partners ... and in excess of the initial fund target of ... entrepreneurs build successful biotechnology companies. Consistent with recent funds, ... promising later stage clinical programs, along with select investments ...
(Date:7/23/2014)... 23, 2014 OncLive® is pleased ... has joined its Strategic Alliance Partnership program. ... program, UNC Lineberger will have the opportunity to ... of its cutting-edge research initiatives, community-directed cancer prevention ... will work with OncLive to educate their peers ...
Breaking Biology Technology:Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 2OncLive Expands Its Strategic Alliance Partnership Program With the Addition of UNC Lineberger Comprehensive Cancer Center 3
Cached News: